Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2001
The combination of taxanes, and especially docetaxel, with an anthracycline seems to be an important part of the chemotherapy regimens used in the adjuvant setting of patients with early-stage node-positive breast cancer patients. Whether sequential or concurrent administration of these drugs is preferable is not yet known, especially in patients with node-negative high risk tumors.
Epistemonikos ID: 0cc610dc5d0ea5ec9dc34362ea3f366bc32c08dc
First added on: May 04, 2024